Effect of Platelet Inhibitors on LIBS Exposure by PECAM-1.2
| Agonist . | Inhibitor . | |||
|---|---|---|---|---|
| 50 ng/mL PGE1 . | 10 U/mL Apyrase . | 5 μmol/L Indomethicin . | 5 μmol/L SQ 29.5 . | |
| 2 mmol/L RGEW | 0 | 9.6 | 2.5 | 0 |
| 2 mmol/L RGDW | 138.1 | 151.8 | 136.5 | 136.5 |
| NM IgG | 6.6 | 17.4 | 0 | 0 |
| PECAM-1.1 | 5.5 | 1.3 | 2.0 | 2.1 |
| PECAM-1.3 | 0 | 0 | 4.5 | 0 |
| PECAM-1.2 | 33.5 | 46.2 | 36.6 | 25.6 |
| Agonist . | Inhibitor . | |||
|---|---|---|---|---|
| 50 ng/mL PGE1 . | 10 U/mL Apyrase . | 5 μmol/L Indomethicin . | 5 μmol/L SQ 29.5 . | |
| 2 mmol/L RGEW | 0 | 9.6 | 2.5 | 0 |
| 2 mmol/L RGDW | 138.1 | 151.8 | 136.5 | 136.5 |
| NM IgG | 6.6 | 17.4 | 0 | 0 |
| PECAM-1.1 | 5.5 | 1.3 | 2.0 | 2.1 |
| PECAM-1.3 | 0 | 0 | 4.5 | 0 |
| PECAM-1.2 | 33.5 | 46.2 | 36.6 | 25.6 |
Platelets were treated with IV.3 Fab fragments (10 μg/mL) before the addition of the indicated agonist or MoAb. MoAbs were used at a final concentration of 10 μg/mL. Numbers shown are the mean fluorescence intensity given by the binding of the LIBS antibody, D3, to platelets after platelet stimulation by the indicated agonist, in the presence of various inhibitors of platelet secondary metabolites or scavengers of ADP release. The mean fluorescence intensity of D3 binding in the presence of buffer alone has been subtracted. Data shown are representative of results obtained in three independent experiments.